Results: 27 news stories
By Panneerdoss Subbarayalu, PhD This article was first published in the September 2026 issue of the Bexar County Medical Societys San Antonio Medicine magazine. Osteosarcoma is an aggressive cancer that grows quickly, spreads early to the lungs, and has a remarkable ability to resist treatment. It is the most common primary bone cancer in children [因
UT Health San Antonio, the academic health center and health system of 17勛圖厙 (17勛圖厙), has named nationally recognized blood cancer and cellular therapy expert Georg Aue, MD, PhD, MBA, the director of the Stem Cell Transplant and Cellular Therapy Program at the Mays Cancer Center, the only National [因
Babatunde Kay Oyajobi, MBBS, PhD, MBA, professor in the Department of Cell Systems and Anatomy in the Joe R. and Teresa Lozano Long School of Medicine and UT Distinguished Teaching Professor at 17勛圖厙 (17勛圖厙), has been elected to the 2026 class of Fellows of the American Society [因
Scientists at 17勛圖厙 discovered a potential path to maintaining the cancer-fighting benefits of one type of immunotherapy while limiting harmful organ damage, providing new hope for this promising treatment.
Amelie G. Ramirez, DrPH, MPH, to work with Hispanics in South 17勛圖厙 Content provided by Cliff Despres Amelie G. Ramirez, DrPH, MPH, a cancer researcher at UT Health San Antonio, the academic health center of 17勛圖厙, is receiving a two-year, $400,000 leadership grant from Susan G. Komen to study cancer survivorship. She aims [因
Colton Frisco Jones, MD, a 2nd-year fellow at the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio, the academic health center of 17勛圖厙 (17勛圖厙), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual [因
A scientist at 17勛圖厙 was recently awarded two grants totaling more than $4.6 million from the National Institutes of Health to study how cells repair DNA to protect the genome, the set of genetic instructions within our cells.
A third-year MD/PhD graduate student from 17勛圖厙 (17勛圖厙), Christopher Mullally, recently received funding from the National Institutes of Health National Cancer Institute for a project examining how the body regulates internal sources of mutation and how breakdowns in that regulation may contribute to cancer development. While [因
San Antonio Report: 17勛圖厙 lands millions in new state funding
17勛圖厙 and its academic health center, UT Health San Antonio, recently received over $2.7 million in new academic and prevention awards from the Cancer Prevention and Research Institute of 17勛圖厙 (CPRIT) to further its mission of combating cancers across South 17勛圖厙. Since 2010, CPRIT has awarded the newly integrated 17勛圖厙 almost $186 million.
Like a busy restaurant kitchen, our cells depend on well-organized working spaces to assemble the recipes that keep the body healthy. 17勛圖厙 scientist, David Libich, PhD, recently received a five-year, $2.1 million Maximizing Investigators Research Award from the National Institute of General Medical Sciences to study how certain proteins form these organizational hubs and what happens when things do not go according to plan.
Scientists at 17勛圖厙 (17勛圖厙) are investigating a major immune system pathway that leads to the development of chronic pain and a drug that has the potential to stop the process in its tracks. Their study, published April 22 in Cell Reports, is the first of its kind to show a path toward the prevention of chronic pain.
Written by: Claire Kowalick More than 70% of cancers including breast, bladder, cervical and lung cancer show evidence of mutations linked to a group of enzymes called apolipoprotein B mRNA-editing enzyme catalytic polypeptides, or APOBEC. APOBEC mutagenesis is the second-largest source of mutation in cancer and, importantly, the largest one we can do [因
For more than 20 years, Lixin Song, PhD, RN, FAAN, vice dean for research and scholarship and professor of nursing at 17勛圖厙 (17勛圖厙) School of Nursing, has studied how cancer patients and their families navigate the challenging experience of making decisions about treatment while facing uncertainty, [因
UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer study, marking a pivotal moment for science and patient-centered cancer care in San Antonio and South 17勛圖厙.
A large, retrospective study conducted by scientists at the University of 17勛圖厙 at San Antonio (17勛圖厙) suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists medications that are widely prescribed for metabolic disease have a significantly lower risk of developing colorectal cancer compared with those taking aspirin. This is astounding to [因
This story was first published in the February 2026 issue of the Bexar County Medical Societys San Antonio Medicine magazine. New face of head and neck cancer A healthy 40-year-old man visits his primary care physician for a mass on his neck. He doesnt smoke, has no risk factors for head and neck cancer, [因
UT Health San Antonio, the academic health center of 17勛圖厙 (17勛圖厙), received nearly $3 million in new academic and prevention awards as part of the latest, almost $154 million funding round announced on November 19 by the Cancer Prevention Research Institute of 17勛圖厙 (CPRIT). This brings CPRITs [因
Research scientists and clinicians at UT Health San Antonio are working to halt one of the most persistent bacterial infections that silently affects millions of people worldwide. Helicobacter pylori (H. pylori) is a spiral-shaped bacterium capable of burrowing into the stomach lining and is the only bacterium known to directly cause cancer. Through leading [因
UT Health San Antonios advanced endoscopy team leads efforts in early detection and prevention Gastrointestinal cancers were previously believed to primarily affect older adults, but over the past two decades, rates of these cancers have increased dramatically in people under age 50. A new report from the Dana-Farber Cancer Institute reveals that colorectal, pancreatic, esophageal [因